Comment on McCarthy, C.; et al. Developing Picornaviruses for Cancer Therapy. Cancers 2019, 11, 685
Conflicts of Interest
References
- McCarthy, C.; Jayawardena, N.; Burga, L.N.; Bostina, M. Developing Picornaviruses for Cancer Therapy. Cancers 2019, 11, 685. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alberts, P.; Tilgase, A.; Rasa, A.; Bandere, K.; Venskus, D. The advent of oncolytic virotherapy in oncology: The Rigvir® story. Eur. J. Pharmacol. 2018, 837, 117–126. [Google Scholar] [CrossRef] [PubMed]
- United-Nations, S.D. Geographic Regions. Available online: https://unstats.un.org/unsd/methodology/m49/ (accessed on 11 February 2020).
- Doniņa, S.; Strēle, I.; Proboka, G.; Auziņš, J.; Alberts, P.; Jonsson, B.; Venskus, D.; Muceniece, A. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015, 25, 421–426. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brūvere, R.; Heisele, O.; Ferdats, A.; Rupais, A.; Muceniece, A. Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation. Acta Med. Litu. 2002, 9 (Suppl. S9), 97–100. [Google Scholar]
- Alberts, P.; Olmane, E.; Brokāne, L.; Krastiņa, Z.; Romanovska, M.; Kupčs, K.; Isajevs, S.; Proboka, G.; Erdmanis, R.; Nazarovs, J.; et al. Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS 2016, 124, 896–904. [Google Scholar] [CrossRef] [PubMed]
- Proboka, G.; Tilgase, A.; Isajevs, S.; Rasa, A.; Alberts, P. Melanoma unknown primary brain metastasis treatment with echo-7 oncolytic virus rigvir: A case report. Front. Oncol. 2018, 8, 43. [Google Scholar] [CrossRef] [PubMed]
- Tilgase, A.; Olmane, E.; Nazarovs, J.; Brokāne, L.; Erdmanis, R.; Rasa, A.; Alberts, P. Multimodality treatment of a colorectal cancer stage IV patient with FOLFOX-4, bevacizumab, rigvir oncolytic virus, and surgery. Case Rep. Gastroenterol. 2018, 12, 457–465. [Google Scholar] [CrossRef] [PubMed]
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alberts, P. Comment on McCarthy, C.; et al. Developing Picornaviruses for Cancer Therapy. Cancers 2019, 11, 685. Cancers 2020, 12, 1775. https://doi.org/10.3390/cancers12071775
Alberts P. Comment on McCarthy, C.; et al. Developing Picornaviruses for Cancer Therapy. Cancers 2019, 11, 685. Cancers. 2020; 12(7):1775. https://doi.org/10.3390/cancers12071775
Chicago/Turabian StyleAlberts, Pēteris. 2020. "Comment on McCarthy, C.; et al. Developing Picornaviruses for Cancer Therapy. Cancers 2019, 11, 685" Cancers 12, no. 7: 1775. https://doi.org/10.3390/cancers12071775
APA StyleAlberts, P. (2020). Comment on McCarthy, C.; et al. Developing Picornaviruses for Cancer Therapy. Cancers 2019, 11, 685. Cancers, 12(7), 1775. https://doi.org/10.3390/cancers12071775